Single Doses of Pediatric Dolutegravir Dispersible Tablets in Neonates Support Multidosing: PETITE-Dolutegravir Study
Owing to the slow postnatal DTG clearance after birth, a multidose strategy of 5 mg DTG-DT q48 for the first 2 weeks of life, followed by q24 through 28 days, was selected for assessment in stage 2.
Authors
- Marizeth Groenewald (ORCID: https://orcid.org/0000-0003-0835-5925)
- Tim Roy Cressey (ORCID: https://orcid.org/0000-0002-8106-0974)
- Adrie Bekker (ORCID: https://orcid.org/0000-0003-3836-3432)
- Samantha du Toit (ORCID: https://orcid.org/0000-0003-3863-0369)
- Edmund V. Capparelli (ORCID: https://orcid.org/0000-0002-1630-0505)
- Helena Rabie (ORCID: https://orcid.org/0000-0001-6336-2963)
- Andrew Owen (ORCID: https://orcid.org/0000-0002-9819-7651)
- Ratchada Cressey (ORCID: https://orcid.org/0000-0003-4346-4422)
- Nicolas Salvadori (ORCID: https://orcid.org/0000-0002-0820-5305)
- Marc Lallemant
- Kanchana Than-in-at (ORCID: https://orcid.org/0000-0001-5120-7501)
- Mark F. Cotton
Institutions
- University of Liverpool (GB)
- Stellenbosch University (ZA)
- University of California San Diego (US)
- Celsus Therapeutics (United Kingdom) (GB)
- Chiang Mai University (TH)
Publication Details
- Journal
- JAIDS Journal of Acquired Immune Deficiency Syndromes
- Published
- 2025-02-20
- DOI
- https://doi.org/10.1097/qai.0000000000003652
- Citations
- 6
- Primary Topic
- Pharmaceutical studies and practices
- Type
- article
- Field-Weighted Citation Impact
- 20.96